title: Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
abstract: Alemtuzumab, a monoclonal antibody directed against human CD52, is used in the treatment of MS. To characterize the impact of anti-CD52 administration, a monoclonal antibody to mouse CD52 (anti-muCD52) was generated and evaluated in EAE mouse models of MS. A single course of anti-muCD52 provided a therapeutic benefit accompanied by a reduction in the frequency of autoreactive T lymphocytes and production of pro-inflammatory cytokines. Examination of the CNS revealed a decrease in infiltrating lymphocytes, demyelination and axonal loss. Electrophysiological assessment showed preservation of axonal conductance in the spinal cord. These findings suggest that anti-CD52 therapy may help preserve CNS integrity.
authors.affiliation: Neuroimmunology Research, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States. Electronic address: michael.turner@genzyme.com.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Turner
authors.affiliation: Neuroimmunology Research, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: Petti T
authors.initials: PT
authors.lastname: Pang
authors.affiliation: Neuroimmunology Research, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Chretien
authors.affiliation: Neuroimmunology Research, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: Evis
authors.initials: E
authors.lastname: Havari
authors.affiliation: Neuroimmunology Research, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: LaMorte
authors.affiliation: Pathology, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: Julian
authors.initials: J
authors.lastname: Oliver
authors.affiliation: Neuroimmunology Research, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: Nilesh
authors.initials: N
authors.lastname: Pande
authors.affiliation: Biologics Discovery, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Masterjohn
authors.affiliation: Biologics Discovery, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: Karen
authors.initials: K
authors.lastname: Carter
authors.affiliation: Biologics Discovery, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: David
authors.initials: D
authors.lastname: Reczek
authors.affiliation: Biologics Discovery, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: William
authors.initials: W
authors.lastname: Brondyk
authors.affiliation: Neuroimmunology Research, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Roberts
authors.affiliation: Neuroimmunology Research, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: Johanne M
authors.initials: JM
authors.lastname: Kaplan
authors.affiliation: Neuroimmunology Research, Genzyme, a Sanofi company, 49 New York Avenue, Framingham, MA 01701, United States.
authors.forename: William M
authors.initials: WM
authors.lastname: Siders
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D001369:Axons / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D000074301:CD52 Antigen; D003711:Demyelinating Diseases / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008969:Molecular Sequence Data
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D018836:Inflammation Mediators
keywords: Alemtuzumab; CD52; Experimental autoimmune encephalomyelitis; Mouse; Multiple sclerosis